✉news HealthMedicine first seen 8 h ago, last 4 h ago, peak #16
Eli Lilly CEO Touts Retatrutide As Next Growth Driver
Original: Eli Lilly CEO Bets On Weight-Loss Medicine Retatrutide As Next Growth Driver, Says Firm’s Future Has ‘Never Been Brighter’
Eli Lilly's chief executive said the company's future has 'never been brighter' as it bets on retatrutide, its experimental obesity and weight-loss drug, to become the next major growth driver. The remark signals confidence that Lilly will extend its lead in the booming weight-loss medicine market alongside its existing blockbuster drugs, keeping investors focused on the drug's development and approval prospects.
Why now: Investors and health watchers are closely following the weight-loss drug race, and the CEO's bullish comments put attention on Lilly's next candidate.
Rank over time, top of the chart is #1. 2 snapshots from 5 h ago to 4 h ago.
Evidence
- Eli Lilly CEO Bets On Weight-Loss Medicine Retatrutide As Next Growth Driver, Says Firm’s Future Has ‘Never Been Brighter’ · stocktwits.com
API: https://socialmediatrends-api.osmike.com/v1/trends/94250